Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Avenue Therapeutics Inc ATXI

Healthcare Drug Manufacturers - Specialty & Generic
Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. The Company is developing three assets including AJ201, an asset for spinal and bulbar muscular atrophy; BAER-101, an oral small molecule selective Gamma-aminobutyric acid receptor A alpha 2 & 3 (GABAA a2, a3) receptor positive... see more

Recent & Breaking News (NDAQ:ATXI)

Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024

GlobeNewswire March 25, 2024

Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights

GlobeNewswire March 18, 2024

Avenue Therapeutics Receives Positive Listing Determination from Nasdaq

GlobeNewswire March 15, 2024

Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting

GlobeNewswire March 11, 2024

Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy

GlobeNewswire February 22, 2024

Sidoti Events, LLC's Virtual January Micro-Cap Conference

Accesswire January 16, 2024

Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference

GlobeNewswire January 11, 2024

Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds

GlobeNewswire January 5, 2024

Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol

GlobeNewswire January 4, 2024

Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

GlobeNewswire January 2, 2024

Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting

GlobeNewswire December 1, 2023

Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

GlobeNewswire November 13, 2023

Avenue Therapeutics Announces Closing of $5.0 Million Public Offering

GlobeNewswire November 2, 2023

Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering

GlobeNewswire October 31, 2023

Avenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire September 5, 2023

Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

GlobeNewswire August 14, 2023

Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

GlobeNewswire August 10, 2023

Avenue Therapeutics Announces High Potency and Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator, BAER-101, Supporting Phase 2 Clinical Study

GlobeNewswire August 1, 2023

Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

GlobeNewswire July 27, 2023

Avenue Therapeutics Announces Agreement with the FDA on the Study Design and Analysis Approach of the Phase 3 Safety Study for IV Tramadol

GlobeNewswire July 25, 2023